ArticleJournal of cardiovascular pharmacology2011
Mitochondria-targeted cardioprotection in aldosteronism.
Article in Journal of cardiovascular pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Resveratrol and beyond: The Effect of Natural Polyphenols on the Cardiovascular System: A Narrative Review.Biomedicines · 2023Review
- Sleep/wake calcium dynamics, respiratory function, and ROS production in cardiac mitochondria.Journal of advanced research · 2021Article
- Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action.Saudi journal of biological sciences · 2021Article
- Quercetin treatment increases HNaunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Potential Implications of Quercetin and its Derivatives in Cardioprotection.International journal of molecular sciences · 2020Review
- Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System inInternational journal of molecular sciences · 2018Article
- Myofibroblast secretome and its auto-/paracrine signaling.Expert review of cardiovascular therapy · 2016Review
- Aldosterone Disrupts the Intercellular Flow of Glucose in Cardiac Muscle.Frontiers in endocrinology · 2015Article
- Small dedifferentiated cardiomyocytes bordering on microdomains of fibrosis: evidence for reverse remodeling with assisted recovery.Journal of cardiovascular pharmacology · 2014Article
- Phosphoproteome mapping of cardiomyocyte mitochondria in a rat model of heart failure.Molecular and cellular biochemistry · 2014Article
- Article
- Atrophic cardiomyocyte signaling in hypertensive heart disease.Journal of cardiovascular pharmacology · 2013Article
- Myofibroblast-mediated mechanisms of pathological remodelling of the heart.Nature reviews. Cardiology · 2013Review
- Reverse remodeling and recovery from cachexia in rats with aldosteronism.American journal of physiology. Heart and circulatory physiology · 2012Article
- Mitochondria play a central role in nonischemic cardiomyocyte necrosis: common to acute and chronic stressor states.Pflugers Archiv : European journal of physiology · 2012Review
- Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Heart failure clinics · 2012Review
- Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol.Journal of cardiovascular pharmacology · 2011Article
- Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer-effector pathway.Experimental and clinical cardiology · 2011Article
- Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones.Progress in cardiovascular diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Chronic aldosterone/salt treatment (ALDOST) is accompanied by an adverse structural remodeling of myocardium that includes multiple foci of microscopic scarring representing morphologic footprints of cardiomyocyte necrosis. Our previous studies suggested that signal-transducer-effector pathway leading to necrotic cell death during ALDOST includes intramitochondrial Ca overloading, together with an induction of oxidative stress and opening of the mitochondrial permeability transition pore (mPTP). To further validate this concept, we hypothesized that mitochondria-targeted interventions will prove to be cardioprotective. Accordingly, 8-week-old male Sprague-Dawley rats receiving 4 weeks ALDOST were cotreated with either quercetin, a flavonoid with mitochondrial antioxidant properties, or cyclosporine A (CsA), an mPTP inhibitor, and compared with ALDOST alone or untreated, age/sex-matched controls. We monitored mitochondrial free Ca and biomarkers of oxidative stress, including 8-isoprostane and H2O2 production; mPTP opening; total Ca in cardiac tissue; and collagen volume fraction to quantify replacement fibrosis, a biomarker of cardiomyocyte necrosis, and employed terminal deoxynucleotidyl transferase dUTP nick end labeling assay to address apoptosis in coronal sections of ventricular myocardium. Compared with controls, at 4 weeks ALDOST we found a marked increase in mitochondrial H2O2 production and 8-isoprostane levels, an increased propensity for mPTP opening, and greater concentrations of mitochondrial free [Ca]m and total tissue Ca, coupled with a 5-fold rise in collagen volume fraction without any terminal deoxynucleotidyl transferase dUTP nick end labeling-based evidence of cardiomyocyte apoptosis. Each of these pathophysiologic responses to ALDOST was prevented by quercetin or cyclosporine A cotreatment. Thus, mitochondria play a central role in initiating the cellular-subcellular mechanisms that lead to necrotic cell death and myocardial scarring. This destructive cycle can be interrupted and myocardium salvaged with its structure preserved by mitochondria-targeted cardioprotective strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.